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Abstract In an effort to determine putative functional relation-
ships between gene expression patterns and drug activity patterns
of 60 human cancer cell lines, a novel method was developed to
discover local associations within cell line subsets. The associa-
tion of drug^gene pairs is an explorative way of discovering gene
markers that predict clinical tumor sensitivity to therapy. Nine
drug^gene networks were discovered, as well as dozens of gene^
gene and drug^drug networks. Three drug^gene networks with
well studied members were discussed and the literature shows
that hypothetical functional relationships exist. Therefore, this
method enables the gathering of new information beyond global
associations. ß 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Recently, Ross et al. [1] used cDNA microarrays to assess
gene expression pro¢les of 60 human cancer cell lines. This
gene expression dataset, together with the independently de-
veloped drug activity dataset recording compounds’ anti-
cancer pro¢les against the same 60 cell lines [2], provided
the opportunity to take a global, systematic look at tumor
molecular biology and pharmacology. These two datasets
were used to discover gene^gene, drug^drug and drug^gene
correlations in tumor cells. Since the gene expression pro¢les
are those for untreated cells, the drug^gene correlations re£ect
sensitivity to therapy rather than the molecular consequences
of therapy. Scherf et al. [3] indicated that some causally re-
lated drug^gene pairs had highly correlated pro¢les. They
used the average-linkage clustering method to assess the rela-
tionships. The major drawback was the di⁄culty in identify-
ing positives from the noise. Butte et al. [4] tried to solve this
problem by data ¢ltering and permutation trials. However,
they found only one hypothetical drug^gene pair.
Here a new strategy was developed to discover additional
biological associations that could not easily be discovered by
already existing methods. The motivation of this work was to
¢nd drug^gene, gene^gene, and drug^drug local associations.
A local association is de¢ned here as an association that may
exist within a cell line subset, but that may not necessarily
exist in the whole cell line set. Anticancer drugs may have
signi¢cantly di¡erent e⁄cacies for di¡erent types of cells
and two drugs may have similar activity patterns only in
certain cell line subsets. Analogously, some genes may be
co-regulated by tissue-speci¢c transcription factors and may
display similar patterns only in cell lines from this tissue.
Under such conditions, global correlations may not exist
and all the biological e¡ects may be embodied in the local
associations. In our approach, the measurements (across 58
cell lines) for each drug or gene were ¢rst partitioned into
several subsets according their probability density distribu-
tion, and then the pair-wise correlations within these subsets
were examined to identify statistically signi¢cant pairs. This
method for determining local associations enabled the discov-
ery of new biological facts and information relating these two
pro¢les.
2. Materials and methods
2.1. Gene expression data and drug activity data
Gene expression was measured in 60 cell lines by microarrays, and
the ratios of the relative mRNA level of each cell line to a common
reference sample pool were log transformed [1]. For each cell line,
drug activity was expressed as the negative logarithm of GI50, where
GI50 was the concentration of the compound needed to cause 50% cell
growth inhibition [5]. A 1376-gene subset with greater expression var-
iations and a well validated 1400-compound subset were selected as
according to Scherf et al. [3] from public databases (http://discover.
nci.nih.gov). Because there were only two prostate cell lines, these two
samples were eliminated. The cell lines used are listed in Table 1.
Thus, there was a 1376U58 gene matrix and a 1400U58 drug matrix,
each row of which was a pro¢le vector. The data were normalized so
that each pro¢le vector had a zero mean and a standard deviation of
one.
2.2. Partitioning of each pro¢le vector into feature subspaces
For every gene or drug pro¢le vector, the 58 measurements (one
measurement per cell line) were partitioned into several subsets ac-
cording to the probability density distribution of the measurements.
The resulting cell line subsets are each called a ‘feature subspace’ (FS).
This partitioning procedure was repeated for all the genes and drugs.
A multi-scale clustering algorithm based on multiple scale theory was
used here [6]. The key idea of multi-scale clustering is that data can be
represented in the transformed space (scale-space) at di¡erent resolu-
tion levels called scales, and any prominent data structure should
survive over many scales. For one-dimensional data, a scale-space
representation of the data points, xk, can be realized by convolving
them with a Gaussian kernel xc of scale size c,
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From the statistical pattern recognition viewpoint, the potential ¢eld
function can be viewed as a special case of the Pazen window density
estimate of the probability density function for a scale size c. The
local minima of this function correspond to the locally highest con-
centration of data points in each cluster, and locating all of them by
optimization algorithms gives a certain classi¢cation of data for that
scale size. The data were then classi¢ed in this way for various scale
sizes. The classi¢cation that survived over the widest range of scales
was chosen as the optimal classi¢cation.
To give prominence to a single gene’s e¡ect, a FS whose gene
expression level varied far from the overall average expression level
was preferable (see Section 4). Therefore, only FSs whose absolute
mean values exceeded 1.0 were used in the following calculations.
2.3. Finding the common feature subspace
For every possible drug^gene pair (gene^gene pair and drug^drug
pair were essentially similar), the intersection of the gene’s FS and the
drug’s corresponding FS containing at least six cell lines was recorded.
FSs with too few cell lines were not interesting and a minimum of six
was required because every tissue category contains at least six mem-
bers (Table 1). Ideally, the gene’s FS, the drug’s FS and their inter-
section should be just the same. Yet, since there were many missing
values in the two pro¢les, and since, according to Golub et al. [7], a
single gene would rarely completely coincide with any phenotype pat-
tern, few such cases were expected. Therefore, common feature sub-
space (CFS) was de¢ned as the intersection that contained the major-
ity of the cell lines appearing in the two FSs. Within the union of the
two FSs, the number of cell lines not belonging to the intersection
should be less than or equal to half the number of cell lines belonging
to the intersection and should also be less than six.
2.4. Forming relevance networks
The Pearson correlation coe⁄cient was calculated within the CFS
for every drug^gene pair. Statistical hypotheses that the correlations
were signi¢cantly di¡erent from zero were tested at a signi¢cance level
of 0.02. For the gene^gene and drug^drug pairs, correlations were
further tested that they not only signi¢cantly di¡ered from zero, but
could also explain at least 50% of the variance [8]. Finally, relevance
networks were formed by grouping pairs sharing common members.
3. Results
3.1. Permutation trials
The method for ¢nding a candidate functional pair is de-
picted in Fig. 1. All pairs were determined in this way and
represented as relevance networks. All the networks obtained
can be found in the supplementary material. Permutation tri-
als were done to test how well the method determines posi-
tives from noise. For each drug and gene, measurements were
randomly permutated 100 independent times. The results are
shown in Table 2. The positives obtained from the true data-
set are signi¢cantly more than those obtained from random-
ized datasets. Only one false positive was reproduced by 100
permutations, so candidate pairs identi¢ed by the method
could rarely be generated through random chance.
3.2. Gene^gene networks
There were, in total, 24 gene^gene networks, 13 of which
were single pairs. Many of the networks contained synonymy
genes, which demonstrated the validity of this approach. One
network listed here (Fig. 2, network 1) contained AKR1C1,
AKR1C3 and AKR1C4, all of which belong to the aldo-keto
reductase family 1 [9].
The largest network contained nine unique genes (Fig. 2,
network 2). They all up-regulated in the CFS having cells with
stromal origin, but down-regulated in blood cells and cells
with epithelial origin. The literature showed that these genes
are related to the metabolism of steroids and fatty acids. For
Table 1
Cancer cell lines and their numerical labels used in this work
Tissue origin Cell line name
Breast (1^8) 1: BT-549, 2: HS578T, 3: MCF7, 4: MCF7/ADF-RES, 5: MDA-MB-231/ATCC, 6: MDA-MB-435, 7: MDA-N,
8: T-47D
CNS (9^14) 9: SNB-19, 10: SNB-75,11: SF-268, 12: SF-295, 13: SF-539, 14: U251
Colon (15^21) 15: COLO205, 16: HCC-2998, 17: HCT-116, 18: HCT-15, 19: HT29, 20: KM12, 21: SW-620
Lung (22^30) 22: A549/ATCC, 23: EKVX, 24: HOP-62, 25: HOP-92, 26: NCI-H226, 27: NCI-H23, 28: NCI-H322M,
29: NCI-H460, 30: NCI-H522
Leukemia (31^36) 31: CCRF-CEM, 32: HL-60, 33: K-562, 34: MOLT-4, 35: RPMI-8226, 36: SR
Melanoma (37^44) 37: LOXIMVI, 38: M14, 39: MALME-3M, 40: SK-MEL-2, 41: SK-MEL-5, 42: SK-MEL-28, 43: UACC-62,
44: UACC-257
Ovarian (45^50) 45: IGROV1, 46: OVCAR-3, 47: OVCAR-4, 48: OVCAR-5, 49: OVCAR-8, 50: SK-OV-3
Renal (51^58) 51: 786-0, 52: A498, 53: ACHN, 54: CAKI-1, 55: RXF-393, 56: SN12C, 57: TK-10, 58: UO-31
CNS: central nervous system.
Fig. 1. Methodology. (1) Each pro¢le vector was partitioned into several FSs. (2) Each FS from the pro¢le vector I was intersected with the
corresponding FS from the pro¢le vector II. If the resulting intersection covered the majority of cell lines from the two FSs, it was called a
CFS. Only the CFS was retained for the next procedure. (3) The correlation coe⁄cient was calculated within the CFS. If the correlation was
statistically di¡erent from zero, the pair was considered as a functional candidate.
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example, PRKAG1 is a subunit of AMPK that is known to
play a key role in regulating both fatty acid and cholesterol
synthesis [10]. Fibronectin was found to regulate membrane
lipid biosynthesis through AMPK [11]. LXRA mediates cross-
talk between fatty acid and cholesterol metabolism [12].
CCND2 is a cyclin gene regulated by the steroid hormone
level [13]. These lines of evidence demonstrate that the net-
work caught the common biological properties of the genes
and imply the genes may represent key positions in the cross-
links of di¡erent signaling pathways.
3.3. Drug^drug networks
There were, in total, 18 drug^drug networks, 16 of which
were single pairs. Many of the networks had chemically re-
lated or biologically related drugs. One network that con-
tained two drugs with known mechanisms is shown in Fig.
2 (network 3). These two drugs are both DNA synthesis in-
hibitors and the biological mechanisms are similar [14]. Their
CFS lacked most of the colon cells and some other epithelial
cells. Both drugs displayed high activity in the CFS, which
indicates that the two drugs more e¡ectively inhibit growth of
blood cells and cells of stromal origin, as compared to epithe-
lial origin. Associating drugs with cells having similar chemo-
therapeutic susceptibilities may provide useful clues in design-
ing e¡ective drug treatment.
3.4. Drug^gene networks
There were, in total, nine drug^gene networks, seven of
which were single pairs. Four of these networks with well
studied members are listed in Fig. 3.
The ¢rst network (Fig. 3, network 1) contained the drug
thaliblastine and the gene caveolin-2 in the CFS of mainly
leukemia cell lines. Thaliblastine inhibits a tumor cell’s mul-
ti-drug resistance (MDR) by direct interaction with the P-gly-
coprotein, a drug transporter localized in the plasma mem-
brane microdomain called caveola [15,16]. Caveolin-2 is one
of the main structural proteins of caveolae and hetero-oligo-
Table 2
Permutation results for drug^gene pairs




Original dataset 131 12
Permutated datasets 58a (0.58b) 1a (0.01b)
aThe sum of 100 independent permutations.
bAverages.
Fig. 2. Examples of gene^gene and drug^drug networks. The ¢rst two networks are examples of gene^gene associations. The third network is
an example of drug^drug associations. Nodes representing the expression levels of a single gene are in white and labels drawn within the nodes
correspond to the GeneCard or GenBank accession codes. Nodes representing measures of susceptibility to a single compound are shaded gray
and labels drawn within the nodes correspond to the compound’s National Cancer Institute NSC number. The genes can be found at
http://bioinfo.weizmann.ac.il or http://www.ncbi.nlm.nih.gov/, and the compounds can be found at http://dtp.nci.nih.gov/docs/dtp_search.html.
The cell line labels in the CFS correspond to those in Table 1. The levels of gene expression or drug activity in each CFS are also indicated.
Further details regarding all the networks found are located as Supplementary Material in the online version of this article.
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mers formed by caveolin-1 and caveolin-2 are the functional
assembly units that drive caveola formation in vivo. Lavie et
al. found that P-glycoprotein-related MDR was evidently as-
sociated with increased caveola number and a massive up-
regulation of caveolin expression [17]. Following their hypoth-
esis that precaveolae and caveolins might facilitate the deliv-
ery of drugs from intracellular compartments to plasma mem-
brane-resident drug transporters [18], we suggested that
caveolin-2 might play a role in bringing thaliblastine to the
vicinity of its molecular target, P-glycoprotein.
The second network (Fig. 3, network 2) contained the drug
tamoxifen and the gene FHL2 in the CFS of mainly leukemia
cell lines. Tamoxifen is an anti-estrogen drug that is widely
used in the therapy of breast cancer. Graham indicated that
tumor sensitivity to tamoxifen might be governed by a com-
plex set of transcriptional coregulators for steroid hormone
receptors [19]. Recently, Zhou et al. found that in breast ep-
ithelium, tamoxifen treatment down-regulated androgen re-
ceptor (AR) expression and a¡ected AR-dependent gene tran-
scriptions [20]. The authors proposed that tamoxifen might
interact with AR to regulate AR target gene transcriptions.
FHL2 encodes a LIM-only protein with four and a half LIM
domains and its over-expression can induce apoptosis [21].
Very interestingly, FHL2 was recently found to be a speci¢c
transcriptional coactivator of the AR [22]. Therefore, it is
possible that the drug tamoxifen and the gene FHL2 might
have a certain kind of interaction in AR-dependent transacti-
vations.
The third network (Fig. 3, network 3) contained two drugs
(Terrein, a 2-cyclopenten-1-one derivative and the drug
698249) as well as two genes (laminin L1 and dystroglycan
1) in the CFS of all leukemia cell lines as well as two colon
cell lines. 2-Cyclopenten-1-one exerts its anticancer activity
through inducing Waf1 gene expression and the K,L-unsatu-
rated carbonyl structure is essential for the drug’s activity [23].
Drug 698249 showed a high positive correlation (0.90) with
Terrein in the CFS. Consistently, drug 698249 also has the
same structural determinants (Fig. 4), which may be an im-
portant clue for understanding its mechanism. Therefore, this
method seems useful (at least in this case) for identifying
molecular structures needed for each drug’s activity. Laminin
L1 encodes an extracellular matrix (ECM) protein subunit and
dystroglycan 1 encodes a laminin receptor. In a recent paper
of Staunton et al. for identifying marker genes that predict
chemosensitivity, they noted that the marker gene sets for a
number of drugs are enriched in cytoskeleton/ECM genes [24].
Therefore, this association is not surprising. It is possible that
cytoskeletal signatures may re£ect cellular components that
in£uence sensitivity to a variety of compounds rather than
functioning as direct targets of compound activity.
The fourth network (Fig. 3, network 4) is an example of
networks with high drug activity and high gene expression.
Fig. 3. Examples of networks between drugs and genes. Symbols are the same as in Fig. 2.
Fig. 4. Structures of two drugs from Fig. 3, network 3. They both
have K,L-unsaturated carbonyl structures that are important for cy-
clopentenone to exert its anticancer activity. Therefore, the similar-
ity of their anticancer mechanisms was suggested.
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The CFS contained most of the melanoma cell lines as well as
two breast cell lines that supposedly originated from melano-
ma [1]. ASAH encodes an acid ceramidase. ASAH mRNA
expression was found to be di¡erent between cancers and their
normal counterparts [25], which suggested that ASAH might
be involved in the neoplastic process. The drugs mechanisms
are unknown at present.
4. Discussion
Scherf et al. [3] suggested the use of a global correlation
coe⁄cient to associate genes and drugs. However, even at a
signi¢cance level of 0.001, there were still about 10 000 drug^
gene pairs whose correlation coe⁄cients were statistically dif-
ferent from zero. The majority of these were false positives,
partly due to the outliers’ dominant contribution to the cor-
relation coe⁄cient. True functional positives of interest can-
not be easily located in such a noisy pair set. Butte [4] used
the permutation method to deduce a very stringent correlation
coe⁄cient threshold. Although they did ¢nd one drug^gene
pair that passed the threshold, the sensitivity seemed too low
(one functional pair out of 33 million drug^gene pairs). The
alternative approach used here had both relatively high sensi-
tivity and high speci¢city. Nine candidate functional drug^
gene networks were found out of 2 million drug^gene pairs.
Some of the networks were veri¢ed in the literature.
The methodology was designed to ¢nd local functional as-
sociations, which enabled the gathering of new information
beyond global associations. The drug^gene networks found
here had only moderate global correlations, which demon-
strated the ine¡ectiveness of using the global approach for
discovery. This methodology had an additional advantage in
a biological sense. Many drugs have complex e¡ects on sev-
eral cross-linked gene networks, making it di⁄cult to observe
the e¡ect of a single gene. The global association approach is
ine⁄cient in such a context, because in the majority of cell
lines, a single gene’s expression level is usually constitutive.
However, in our approach, only FSs with gene expression
obviously up-regulated or down-regulated were used for fur-
ther calculations. Therefore, this approach in some sense sim-
ulated the e¡ect of gene knockout or over-expression, and
gave prominence to a single gene’s e¡ect. It is interesting to
note that the majority of CFSs found here contained cell lines
from the same origin (e.g. tissue origin; stromal or epithelial
type).
This method was unsupervised and could easily be scaled
up. One only needs to provide the speci¢city control param-
eters of the CFSs. Such parameters could be adjusted on the
trade-o¡ between sensitivity and speci¢city. Furthermore,
although we applied this approach to a small subset of the
original database, it could be easily scaled up with no mod-
i¢cation. The methodology was relatively insensitive to the
outliers which can bias the global correlation coe⁄cient.
Here, multi-scale clustering was used to obtain FSs, because
it has two advantages over other unsupervised methods. First,
it automatically determines the cluster number objectively.
Second, the resulting classi¢cation re£ects the natural under-
lying structure of the original data.
This approach has several limitations. First, the gene ex-
pression pro¢les were collected in untreated cell lines. There-
fore, the relationships established between drugs and genes
were correlative and not causal. Second, this method did
not take into account the synergetic e¡ects of di¡erent genes.
In fact, drug e⁄cacy is a¡ected by a set of genes, and they
should be considered simultaneously. Third, local associations
in the FSs beyond our de¢nition could not be found by this
approach. An example is the known functional pair of the
drug ASNS and the gene L-asparaginase [3]. The drug and
gene displayed extremely high negative correlation in six leu-
kemia cell lines but only moderately high negative correlation
in all cell lines. This is a good example illustrating the value of
local associations. However, their measurements in these cell
lines were very di¡erent and belonged to di¡erent FSs in our
results, so we failed to ¢nd this pair. This pair suggested
subsets other than our FS de¢nition might also be biologically
signi¢cant. These limitations indicate the direction of future
research.
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